Alzinova AB (FRA:78D) Short Percentage of Float


FRA:78D Alzinova AB FRA:78D
21 GF Score
Price €0.03
! 1 Warning Sign
View Full Analysis

What is Alzinova AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:78D vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Alzinova AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alzinova AB Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzinova AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Alzinova AB's Short Percentage of Float falls into.


FRA:78D
21GF Score
Alzinova AB FRA:78D
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzinova AB Business Description

Other Exchanges ALZ:Sweden78D:Germany
Address Entreprenorsstraket 10, Molndal, SWE, 431 53
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is developing ALZ-101, an oligomer-specific therapeutic vaccine currently advancing toward Phase 2 clinical development, and ALZ-201, a monoclonal antibody targeting toxic amyloid-beta (AB) oligomers, which is in preclinical development. The company's proprietary ABCC peptide technology is focused on disease-modifying treatments for Alzheimer's disease.
21GF Score

Get the complete analysis for FRA:78D

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price